Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Oct 09, 2022 12:23pm
230 Views
Post# 35014816

SurvivalNet

SurvivalNet

This US based company’s website has over 1.3 Million monthly visitors and that’s a lot for a specialized digital media company. They are very active in various social media platforms, arranging events/conferences for medical care professionals have TV streaming channels etc. targeting oncologists and cancer patients. So TH1902 being advertised on their website bring the exposure to the trial and speed up the enrolment of patients during the process.

 

“SurvivorNet is the country's leading platform for cancer information, serving 2.5 million people per month who are looking for help making better decisions about their care. The platform was built in collaboration with leading comprehensive cancer centers and features top physicians delivering highly detailed information about specific cancers. SurvivorNet also has produced thousands of stories intended to provide hope and inspiration for patients.”

 

Breast Cancer Clinical Trial: TH1902 in Patients With Advanced Solid Tumors

 

survivornet News & Press Releases | PR Newswire

 

https://www.crunchbase.com/organization/survivornet/technology

<< Previous
Bullboard Posts
Next >>